Trials / Completed
CompletedNCT03917628
Pharmacokinetics and Safety in Healthy Volunteers
Pharmacokinetics and Safety of SCT630 in Healthy Subjects: a Randomized, Double-blind, Single Dose Clinical Phase I Study.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCT630 | SCT630 single s.c. injection |
| DRUG | adalimumab-EU source | adalimumab-EU source single s.c. injection |
Timeline
- Start date
- 2019-05-29
- Primary completion
- 2019-11-04
- Completion
- 2019-11-04
- First posted
- 2019-04-17
- Last updated
- 2021-01-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03917628. Inclusion in this directory is not an endorsement.